drugset / Trial / NCT07552649

Matched Sibling Allogenic Stem Cell Transplantation With Adoptive Immunotherapy With Regulatory And Conventional T Cells For High Risk Acute Myeloid Leukemia

NCT07552649 ↗

Phase 2 Not yet recruiting 28 enrolled Antonio Pierini
NaSingle-groupOpen-labelTreatment

Summary

The study is a multicentric, interventional study that evaluates the efficacy of allogeneic HLA-matched allo-HSCT consisting of myeloablative conditioning coupled with donor Treg/Tcon adoptive immunotherapy for high-risk AML patients.

Timeline

Start
2026-04
Primary completion
2028-04
Completion
2030-04

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject CD34+ hematopoietic progenitor cells Unknown — —
Subject Treg/Tcon adoptive immunotherapy Cell therapy — —